Raymond James Financial Services Advisors, Inc. Checkpoint Therapeutics, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	BUY	$1.02 - $10.6 $8,904 - $92,538	8,730 Added 11.82%	82,557 $86,000
Q2 2022 Aug 12, 2022	BUY	$0.97 - $1.77 $41,542 - $75,803	42,827 Added 138.15%	73,827 $76,000
Q4 2021 Feb 08, 2022	BUY	$2.68 - $4.46 $5,360 - $8,920	2,000 Added 6.9%	31,000 $96,000
Q3 2021 Nov 02, 2021	BUY	$2.5 - $3.53 $21,800 - $30,781	8,720 Added 43.0%	29,000 $96,000
Q2 2021 Aug 11, 2021	BUY	$2.36 - $3.2 $2,655 - $3,600	1,125 Added 5.87%	20,280 $60,000
Q1 2021 May 14, 2021	BUY	$2.6 - $4.16 $49,803 - $79,684	19,155 New	19,155 $60,000

Others Institutions Holding CKPT

# of Institutions

Shares Held

1.91M

Call Options Held

Put Options Held

View Full List

About Checkpoint Therapeutics, Inc.

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $351M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

More about CKPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account